Related Experiment Video
Updated: Dec 18, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Bronchoscopic intratumoural therapies for non-small cell lung cancer
Andrew DeMaio1, Daniel Sterman2
1NYU PORT (Pulmonary Oncology Research Team), Division of Pulmonary, Critical Care, and Sleep Medicine, NYU Langone Health/NYU Grossman School of Medicine, New York, NY, United States.
Abstract:
The past decade has brought remarkable improvements in the treatment of non-small cell lung cancer (NSCLC) with novel therapies, such as immune checkpoint inhibitors, although response rates remain suboptimal. Direct intratumoural injection of therapeutic agents via bronchoscopic approaches poses the unique ability to directly target the tumour microenvironment and offers several theoretical advantages over systemic delivery including decreased toxicity. Increases in understanding of the tumour microenvironment and cancer immunology have identified many potential options for intratumoural therapy, especially combination immunotherapies. Herein, we review advances in the development of novel bronchoscopic treatments for NSCLC over the past decade with a focus on the potential of intratumoural immunotherapy alone or in combination with systemic treatments.
Insights
Novel bronchoscopic treatments offer targeted intratumoral immunotherapy for non-small cell lung cancer (NSCLC). This approach aims to improve suboptimal response rates seen with current therapies by directly targeting the tumor microenvironment.
Area of Science:
- Oncology
- Immunology
- Pulmonology
Background:
- Non-small cell lung cancer (NSCLC) treatment has advanced with immune checkpoint inhibitors, but response rates are still suboptimal.
- Direct intratumoral injection via bronchoscopy offers advantages over systemic delivery, including reduced toxicity and direct targeting of the tumor microenvironment.
- Advances in understanding the tumor microenvironment and cancer immunology have revealed new therapeutic targets.
Purpose of the Study:
- To review recent advances in bronchoscopic treatments for NSCLC over the past decade.
- To focus on the potential of intratumoral immunotherapy, alone or in combination with systemic treatments, for NSCLC.
- To highlight the advantages of direct intratumoral injection for targeting the tumor microenvironment.
Main Methods:
- Review of scientific literature on novel bronchoscopic treatments for NSCLC.
- Analysis of developments in intratumoral immunotherapy over the last ten years.
- Focus on combination strategies involving intratumoral and systemic therapies.
Main Results:
- Significant progress has been made in developing novel bronchoscopic therapeutic approaches for NSCLC.
- Intratumoral immunotherapy shows promise for directly targeting the NSCLC tumor microenvironment.
- Combination therapies, including intratumoral immunotherapy with systemic treatments, are being explored to enhance efficacy.
Conclusions:
- Bronchoscopic delivery of intratumoral therapies represents a promising strategy for NSCLC treatment.
- Further research into intratumoral immunotherapy, particularly in combination regimens, is warranted to improve patient outcomes.
- Direct targeting of the tumor microenvironment via bronchoscopy offers a potential avenue to overcome limitations of current systemic therapies.
